



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/076,551	02/19/2002	Michael R. Johnson	217973US96	1464

22850 7590 09/12/2003

OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C.
1940 DUKE STREET
ALEXANDRIA, VA 22314

EXAMINER

MCKENZIE, THOMAS C

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 09/12/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	10/076,551	JOHNSON, MICHAEL R.
	Examiner Thomas McKenzie Ph.D.	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 07 August 2003.

2a) This action is **FINAL**. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-11,14-38 and 42-50 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) Claim(s) _____ is/are allowed.

6) Claim(s) 1-11,14-17,19,21-23,27,29,30 and 50 is/are rejected.

7) Claim(s) 18,20,24-26,28,31-38 and 42-49 is/are objected to.

8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on _____ is: a) approved b) disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:

1. Certified copies of the priority documents have been received.

2. Certified copies of the priority documents have been received in Application No. _____.

3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5&7.

4) Interview Summary (PTO-413) Paper No(s). _____.

5) Notice of Informal Patent Application (PTO-152)

6) Other: _____.

DETAILED ACTION

1. This action is in response to an election filed on 8/7/03. There are seventy-six claims pending and forty-five under consideration. Claims 1-11, 14-38, and 42-48 are compound claims. Claim 49 is a composition claim. Claim 50 is a use claim. This is the first action on the merits. The application concerns some acyl guanidine linked phenol compounds, compositions, and uses thereof.

Election/Restrictions

2. Applicant's election with traverse of Group VII, the phenyl compounds, and claim 50, the hydration method in Paper No. 9 is acknowledged. The traversal is on the ground(s) that no search burden is present. This is not found persuasive because according to MPEP §803 "For purposes of the initial requirement, a serious burden on the examiner may be *prima facie* shown if the examiner shows by appropriate explanation of separate classification, or separate status in the art, or a different field of search as defined in MPEP § 808.02. That *prima facie* showing may be rebutted by appropriate showings or evidence by the applicant." Applicant pointed to no errors in the Examiners analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL.

3. Claims 51-81 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected inventions, there being no allowable

generic or linking claim. Applicant timely traversed the restriction (election) requirement in Paper No. 8.

Title

4. After restriction, the title of the invention is not descriptive. A new title is required that is clearly indicative of the invention to which the claims are directed. The following title is suggested: addition of the phrase "Phenolic Guanidine" at the beginning of the title.

Abstract

5. Applicant is reminded of the proper content of an abstract of the disclosure. A patent abstract is a concise statement of the technical disclosure of the patent and should include that which is new in the art to which the invention pertains. The abstract should describe the disclosure sufficiently to assist readers in deciding whether there is a need for consulting the full patent text for details. The abstract is too short and generic. Examiner suggests claim 1, lines 1-25 including the figure, and the utility.

Drawings

6. Applicant has submitted two pages of drawings but the Examiner can find no brief description of these drawings in the specification.

Claim Rejections - 35 USC § 112

7. Claim 50 is rejected under 35 U.S.C. 112, first paragraph, because the specification does not reasonably provide enablement for promoting hydration of

mucosal surfaces. The specification does not enable any physician skilled in the art of medicine, to use the invention commensurate in scope with these claims. “The factors to be considered [in making an enablement rejection] have been summarized as the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims”, *In re Rainer*, 146 USPQ 218 (1965); *In re Colianni*, 195 USPQ 150, *Ex parte Formal*, 230 USPQ 546.

a) Determining if any particular claimed compound would promote hydration of mucosal surfaces would require synthesis of the compound, formulation into a suitable dosage form, and subjecting it clinical trials with a number of fundamentally different pulmonary diseases described below, or to testing them in an assay known to be correlated to clinical efficacy of such treatment. This is a large degree of experimentation. b) The direction concerning promoting hydration of mucosal surfaces is found in lines 10-11, page 8 and in lines 21-25, page 19, which merely states Applicant's' intention to do so. Applicant describe formulations in lines 4-7, page 20 and the passage spanning line 24, page 20 to line 21, page 21. There are no working examples of any formulated product.

Doses required to practice their invention are described in lines 8-14, page 24 and the lines 21-25 of the same page. A 2,000-fold range of doses is recommended with a preferred dose of 0.2mg/day. It is unclear how that dosage was determined since there is no tested data in the specification. There is a *in vitro* assay drawn to blocking sodium channels described in the passage spanning line 8, page 26 to line 5, page 27 with no data. It is unclear if this assay is correlated to promoting hydration of mucosal surfaces. Applicant does not assert so and it is not art-recognized as being so correlated. It is also unclear if any of the presently claimed compounds were tested in this assay. There is reference to an *in vivo* assay for mucociliary clearance in sheep described in lines 11-14, page 29 without data. It would appear that this *in vivo* assay is merely prophetic. This assay for mucociliary clearance would seem to be unrelated to promoting hydration of mucosal surfaces.

- c) There is no working example of treatment of any disease in man or animals.
- d) The nature of the invention is clinical treatment of disease, which involves physiological activity.
- e) The state of the clinical arts in mucosal hydration is provided by Barrett (Annu. Rev. Physiol.) who reports in the abstract that chloride ion, not the sodium ion measured by Applicant, is the "major determinant of mucosal hydration". While chloride anion is often accompanied by

sodium cation, both potassium and calcium are also important balancing counter ions in living cells. A transporter that moves both sodium and potassium, presumably in equal amounts is discussed in the paragraph spanning pages 542-543. Potassium channels and their role in chloride transport are discussed on page 544. An atypical, and less understood calcium channel, which moves chloride is discussed on page 547.

f) The artisan using Applicant's invention would be a physician with a MD degree and several years of experience. g) It is well established that "the scope of enablement varies inversely with the degree of unpredictability of the factors involved", and physiological activity is generally considered to be an unpredictable factor. See *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). h) The scope of the claims involves all of the thousands of compounds of claim 1. The term "promoting hydration of mucosal surfaces" reads on promoting hydration in sick mammals with below normal mucosal surface hydration, promoting hydration in sick mammals with normal mucosal surface hydration, promoting hydration in sick mammals with above normal mucosal surface hydration, for example in someone suffering from edema. The latter would appear dangerous. It would read on doing these things in well, asymptomatic mammals. The

specification fails to teach any benefit to be gained from such actions. Thus, the scope of claim is very broad.

MPEP §2164.01(a) states, “A conclusion of lack of enablement means that, based on the evidence regarding each of the above factors, the specification, at the time the application was filed, would not have taught one skilled in the art how to make and/or use the full scope of the claimed invention without undue experimentation. *In re Wright*, 999 F.2d 1557, 1562, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993).” That conclusion is clearly justified here and undue experimentation will be required to practice Applicant's' invention.

Claim Rejections - 35 USC § 103


8. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-11, 14-17, 19, 21-23, 27, 29, and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Epan (British Journal of Cancer). The reference teaches the compound with registry number 134788-24-2 shown below. The Applicant claims the compound of formula (I) with X = chlorine, Y = N(R²)₂, R¹ = R² = R³ = R⁶ = R⁷ = R^L = hydrogen, R⁴ = (A), o = p = 2, x = a bond, and the sum of o and p of 4. The reference teaches a compound X = chlorine, Y = N(R²)₂, R¹ = R²

$= R^3 = R^6 = R^7 = R^L =$ hydrogen, $R^4 = (A)$, $o = p = 1$, $x =$ a bond, and the sum of o and $p = 2$. The compound is shown in the reference in the table on page 249. The compound is called HBA.

The difference between the claimed and taught compounds is the length of the linking chain between the guandinine group and the phenolic benzene ring. It has been long established that a structural relationship varying the size of a linking carbon chain is *per se* obvious. Specifically, *In re Shetty*, 195 USPQ 753, *In re Wilder*, 195 USPQ 426 and *Ex Parte Greshem* 121 USPQ 422 all feature a compound with a C_2 -link rejected over a compound with a C_1 link. Similarly, *In re Chupp*, 2 USPQ 2nd 1437 and *In re Coes*, 81 USPQ 369 have a C_1 link unpatentable over a C_2 link. *Ex parte Ruddy* 121 USPQ 427 has a C_3 link unpatentable over a C_1 link. *Ex parte Nathan*, 121 USPQ 349 found the insertion of a C_2H_4 link obvious. In all of these cases, the variation was *per-se* obvious and did not require a specific teaching. In particular, the applicant is instructed to look to both *Ex parte Nathan*, 121 USPQ 349 and *Ex parte Ruddy* 121 USPQ 427 where the insertion of an ethylene functionality was found to be obvious over that of the prior art.



Data for the inhibition of sodium transport, the same screening assay used by Applicant, is presented in the same table. The compound is 18-fold more potent


than Amiloride in the screening assay. Synthesis of the compound is described in the third paragraph on page 247. Substitution of the appropriate starting material would allow synthesis of the compound with $o = p = 4$. Thus, this is an enabling reference for Applicant's claimed compound.

Allowable Subject Matter

9. Claims 18, 20, 24-26, 28, 31-38, and 42-49 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Conclusion

10. Please direct any inquiry concerning this communication or earlier communications from the Examiner to Thomas C McKenzie, Ph. D. whose telephone number is (703) 308-9806. The FAX number for amendments is (703) 872-9306. The PTO presently encourages all applicants to communicate by FAX. The Examiner is available from 8:30 to 5:30, Monday through Friday. If attempts to reach the Examiner by telephone are unsuccessful, you can reach the Examiner's supervisor, Mukund Shah at (703) 308-4716. Please direct general inquiries or any inquiry relating to the status of this application to the receptionist whose telephone number is (703) 308-1235.


Thomas C. McKenzie, Ph.D.
Patent Examiner
Art Unit 1624

TCMcK

